110 related articles for article (PubMed ID: 38517251)
41. Application of temperature-dependent and steered molecular dynamics simulation to screen anti-dengue compounds against Marburg virus.
Rabaan AA; Almansour ZH; Al Bshabshe A; Halwani MA; Al-Subaie MF; Al Kaabi NA; Alshamrani SA; Alshehri AA; Nahari MH; Alqahtani AS; Alhajri M; Alissa M
J Biomol Struct Dyn; 2024 Jan; ():1-20. PubMed ID: 38234048
[TBL] [Abstract][Full Text] [Related]
42. Identification and validation of novel non-nucleoside class of molecules inhibiting the dengue virus replication.
Roy KK; Jyothi D; Paul U; Sukla S
J Biomol Struct Dyn; 2023; 41(23):13993-14002. PubMed ID: 36970872
[TBL] [Abstract][Full Text] [Related]
43. Phenolic compounds of Theobroma cacao L. show potential against dengue RdRp protease enzyme inhibition by In-silico docking, DFT study, MD simulation and MMGBSA calculation.
Huq AKMM; Roney M; Dubey A; Nasir MH; Tufail A; Aluwi MFFM; Ishak WMW; Islam MR; Tajuddin SN
PLoS One; 2024; 19(3):e0299238. PubMed ID: 38483871
[TBL] [Abstract][Full Text] [Related]
44. Screening of potential phytomolecules against MurG as drug target in nosocomial pathogen
Lokhande KB; Pawar SV; Madkaiker S; Shrivastava A; Venkateswara SK; Nawani N; Wani M; Ghosh P; Singh A
J Biomol Struct Dyn; 2024; 42(1):495-508. PubMed ID: 36974974
[TBL] [Abstract][Full Text] [Related]
45. Quassinoids from Eurycoma longifolia with antiviral activities by inhibiting dengue virus replication.
He X; Zheng Y; Tian C; Wen T; Yang T; Yu J; Fang X; Fan C; Liu J; Yu L
Phytomedicine; 2023 Feb; 110():154650. PubMed ID: 36649670
[TBL] [Abstract][Full Text] [Related]
46. Repurposing immune boosting and anti-viral efficacy of
Dinata R; Nisa N; Arati C; Rasmita B; Uditraj C; Siddhartha R; Bhanushree B; Saeed-Ahmed L; Manikandan B; Bidanchi RM; Abinash G; Pori B; Khushboo M; Roy VK; Gurusubramanian G
J Biomol Struct Dyn; 2024; 42(1):43-81. PubMed ID: 37021347
[TBL] [Abstract][Full Text] [Related]
47. Repositioning Therapeutics for SARS-CoV-2: Virtual Screening of Plant-based Anti-HIV Compounds as Possible Inhibitors against COVID-19 Viral RdRp.
Murali M; Gowtham HG; Ansari MA; Alomary MN; Alghamdi S; Almehmadi M; Singh SB; Shilpa N; Aiyaz M; Kalegowda N; Ledesma AE; Amruthesh KN
Curr Pharm Des; 2022; 28(12):969-980. PubMed ID: 35796443
[TBL] [Abstract][Full Text] [Related]
48. Discovery of Ganoderma lucidum triterpenoids as potential inhibitors against Dengue virus NS2B-NS3 protease.
Bharadwaj S; Lee KE; Dwivedi VD; Yadava U; Panwar A; Lucas SJ; Pandey A; Kang SG
Sci Rep; 2019 Dec; 9(1):19059. PubMed ID: 31836806
[TBL] [Abstract][Full Text] [Related]
49. Unearthing the inhibitory potential of phytochemicals from
Das D; Mallick B; Sinha S; Ganguli S; Samanta D; Banerjee R; Roy D
J Biomol Struct Dyn; 2023 Dec; ():1-18. PubMed ID: 38157248
[TBL] [Abstract][Full Text] [Related]
50. Screening of phytochemicals from
Yasmeen N; Ahmad Chaudhary A; K Niraj RR; Lakhawat SS; Sharma PK; Kumar V
J Biomol Struct Dyn; 2023 Dec; ():1-43. PubMed ID: 38141177
[TBL] [Abstract][Full Text] [Related]
51. Pharmacophore-Model-Based Drug Repurposing for the Identification of the Potential Inhibitors Targeting the Allosteric Site in Dengue Virus NS5 RNA-Dependent RNA Polymerase.
Kumar S; Bajrai LH; Faizo AA; Khateb AM; Alkhaldy AA; Rana R; Azhar EI; Dwivedi VD
Viruses; 2022 Aug; 14(8):. PubMed ID: 36016449
[TBL] [Abstract][Full Text] [Related]
52. Peptide-ligand conjugate based immunotherapeutic approach for targeted dismissal of non-structural protein 1 of dengue virus: A novel therapeutic solution for mild and severe dengue infections.
Srivastava V; Godara P; Jena SP; Naik B; Singh S; Prajapati VK; Prusty D
Int J Biol Macromol; 2024 Mar; 260(Pt 2):129562. PubMed ID: 38246445
[TBL] [Abstract][Full Text] [Related]
53. Identification of RdRp inhibitors against SARS-CoV-2 through E-pharmacophore-based virtual screening, molecular docking and MD simulations approaches.
Rehman HM; Sajjad M; Ali MA; Gul R; Naveed M; Aslam MS; Shinwari K; Bhinder MA; Ghani MU; Saleem M; Rather MA; Ahmad I; Amin A
Int J Biol Macromol; 2023 May; 237():124169. PubMed ID: 36990409
[TBL] [Abstract][Full Text] [Related]
54.
Sharma P; Joshi T; Joshi T; Mathpal S; Maiti P; Nand M; Chandra S; Tamta S
J Biomol Struct Dyn; 2023 Feb; 41(2):646-658. PubMed ID: 34854365
[TBL] [Abstract][Full Text] [Related]
55. Virtual screening of eighteen million compounds against dengue virus: Combined molecular docking and molecular dynamics simulations study.
Mirza SB; Salmas RE; Fatmi MQ; Durdagi S
J Mol Graph Model; 2016 May; 66():99-107. PubMed ID: 27054972
[TBL] [Abstract][Full Text] [Related]
56. Blueprint of epitope-based multivalent and multipathogenic vaccines: targeted against the dengue and zika viruses.
Sarkar B; Ullah MA; Araf Y; Das S; Hosen MJ
J Biomol Struct Dyn; 2021 Nov; 39(18):6882-6902. PubMed ID: 32772811
[TBL] [Abstract][Full Text] [Related]
57. Molecular insights to the binding interactions of APNS containing HIV-protease inhibitors against SARS-CoV-2 M
Purohit P; Dash JJ; Muya JT; Meher BR
J Biomol Struct Dyn; 2023 Jun; 41(9):3900-3913. PubMed ID: 35388744
[TBL] [Abstract][Full Text] [Related]
58. A Synthetic Bioactive Peptide Derived from the Asian Medicinal Plant
Panya A; Sawasdee N; Songprakhon P; Tragoolpua Y; Rotarayanont S; Choowongkomon K; Yenchitsomanus PT
Viruses; 2020 Nov; 12(11):. PubMed ID: 33172110
[TBL] [Abstract][Full Text] [Related]
59. Virtual screening and structure-based 3D pharmacophore approach to identify small-molecule inhibitors of SARS-CoV-2 M
Elseginy SA
J Biomol Struct Dyn; 2022; 40(24):13658-13674. PubMed ID: 34676801
[TBL] [Abstract][Full Text] [Related]
60. Antiviral Activity of an Indole-Type Compound Derived from Natural Products, Identified by Virtual Screening by Interaction on Dengue Virus NS5 Protein.
García-Ariza LL; González-Rivillas N; Díaz-Aguirre CJ; Rocha-Roa C; Padilla-Sanabria L; Castaño-Osorio JC
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
